RDIF And Rostec Announced The Release Of A Drug For COVID-19 Based On Blood Plasma

Table of contents:

RDIF And Rostec Announced The Release Of A Drug For COVID-19 Based On Blood Plasma
RDIF And Rostec Announced The Release Of A Drug For COVID-19 Based On Blood Plasma

Video: RDIF And Rostec Announced The Release Of A Drug For COVID-19 Based On Blood Plasma

Отличия серверных жестких дисков от десктопных
Video: Russia's one-dose 'Sputnik Light' vaccine will cost less than $10. 2023, January
Anonim

RDIF and Rostec announced the release of a drug for COVID-19 based on blood plasma

The drug will be produced on the basis of plasma from donors who have had coronavirus infection.

RDIF and Rostec announced the release of a drug for COVID-19 based on blood plasma
RDIF and Rostec announced the release of a drug for COVID-19 based on blood plasma

Image Credit Flickr Tom Wolf

The Natsimbio holding of the state enterprise Rostec has developed a universal technology for the production of immunoglobulins for intravenous use. On its basis, the drug "BioGam" was created, which has already passed the first stage of clinical trials, the press service of the Russian Direct Investment Fund (RDIF) reports.

At the moment, Natsimbio, in partnership with RDIF, is attracting investments for the purchase of equipment, conducting clinical trials and registering the drug. In the future, the production of immunoglobulin containing antibodies against SARS-Cov-2 will be organized according to the full technological cycle at four branches of the national manufacturer of immunobiological preparations "Microgen" holding "Natsimbio" in Perm, Nizhny Novgorod, Tomsk and Ufa. An important condition for launching production is the availability of raw materials, that is, the blood plasma of donors, the RDIF said.

It should be noted that immunoglobulin therapy is widely used all over the world to treat patients with immunodeficiencies, autoimmune, neurological and other serious diseases. At the same time, the production of such drugs is technologically more complicated and more expensive than the production of chemical pharmaceutical products, including due to the fact that the only source of raw materials is donor plasma. To ensure the safety of the drug, a long planning and production cycle is required: at least 12 months must pass from the moment of plasma collection to the release of the finished product.

Popular by topic